AAL

Bears Don't Think Celldex Therapeutics, Inc. (CLDX) is Done Falling

Celldex Therapeutics, Inc. (CLDX) is yet another biotech victim

Apr 27, 2015 at 3:22 PM
facebook X logo linkedin


Celldex Therapeutics, Inc. (NASDAQ:CLDX) is following the rest of the biotech sector lower today, dropping 13% to trade at $26.17. In fact, the equity has been placed on the short-sale restricted list. Traders have gone to the options pits to place bearish bets, with puts crossing at three times the normal intraday pace. It appears buy-to-open activity is taking place at the May 24 put. This means traders expect CLDX to fall at least another 8.3% before front-month options expire at the close on Friday, May 15.

Put buying was popular on CLDX even before today, though. The equity's 50-day International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) put/call volume ratio of 0.63 is only 2 percentage points from an annual bearish extreme. This means puts have been bought to open over calls at a faster-than-usual pace during the past 10 weeks.

However, analysts have a completely different take on the shares. All eight brokerage firms with coverage on the stock rate it a "strong buy."

It's rare to see Celldex Therapeutics, Inc. (NASDAQ:CLDX) struggling like this. The shares have more than doubled in the past 12 months, and have outpaced the broader S&P 500 Index (SPX) by nearly 31 percentage points during the past three months. As such, it's possible some of the recent put buying could be a result of shareholders protecting paper profits against any unexpected pullbacks.

 

Two High-Octane Trade Ideas. One Simple Goal: Intraday Profits.

Dynamite Day Trading Signals delivers two same-day options trades every week — powered by proprietary intraday analysis and 43+ years of trading expertise.

But this isn’t just another stream of alerts.

It’s a structured plan with clear entry and exit points – designed for traders who want to act fast, trade smart, and wrap up gains before the closing bell.

No guesswork. No overnight exposure – Just two well-researched setups per week — whether you prefer buying premium or selling it.

And the results speak for themselves: subscribers have locked in +245.8% total profit over the last six months (since inception!).

👉 Start your one-month trial now for just $10, and be ready for the next trade alert.